Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|June 17, 2015
Pharmacists in Ambulatory Care as Non-Providers
Mollie Scott, PharmD, details the ways in which pharmacists can contribute to patient care in an ambulatory setting despite not having provider status.
Advertisement
Mollie Scott, PharmD, details the ways in which pharmacists can contribute to patient care in an ambulatory setting despite not having provider status.
This video was shot at ASHP's Summer Meetings and Exposition in Denver in June 2015.
Advertisement
Related to this article
Authors of a pharmacist-directed transitions of care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Bridging the Gap: Pharmacist Experiences Obtaining DEA Licenses
2
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
3
Expert Q&A: Pharmacists Address Pneumococcal Vaccine Hesitancy and Screening Complexity in Transitions of Care
4
Etentamig Reduces Risk of Progression or Death by 60% in Relapsed/Refractory Multiple Myeloma
5